Research ArticleOriginal Article

Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients: a prospective single-center randomized study

Long Yuan, Xiaowei Qi, Yi Zhang, Xinhua Yang, Fan Zhang, Linjun Fan, Li Chen, Kongyong Zhang, Ling Zhong, Yanling Li, Sijie Gan, Wenying Fu and Jun Jiang
Cancer Biology & Medicine November 2018, 15 (4) 452-460; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0270

References

  1. 1.↵
    2. Torre LA,
    3. Bray F,
    4. Siegel RL,
    5. Ferlay J,
    6. Lortet-Tieulent J,
    7. Jemal A.
    Global cancer statistics, 2012. CA: Cancer J Clin. 2015; 65: 87–108.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Bray F,
    3. Ferlay J,
    4. Soerjomataram I,
    5. Siegel RL,
    6. Torre LA,
    7. Jemal A.
    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. Published online first: September 12, 2018. DOI: 10.3322/caac.21492.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Cabanes PA,
    3. Salmon RJ,
    4. Vilcoq JR,
    5. Durand JC,
    6. Fourquet A,
    7. Gautier C, et al.
    Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet. 1992; 339: 1245–8.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Cady B.
    Sentinel lymph node biopsy as an alternative to routine axillary lymph node dissection in breast cancer patients. J Surg Oncol. 2001; 77: 149–52.
    OpenUrlPubMed
  5. 5.↵
    2. Noguchi M,
    3. Tsugawa K,
    4. Miwa K,
    5. Taniya T.
    Sentinel lymph node biopsy and axillary lymph node dissection. Gan to Kagaku Ryoho. 2000; 27: 961–6.
    OpenUrlPubMed
  6. 6.↵
    2. Giuliano AE,
    3. Kirgan DM,
    4. Guenther JM,
    5. Morton DL.
    Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220: 391–401.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Krag DN,
    3. Weaver DL,
    4. Alex JC,
    5. Fairbank JT.
    Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993; 2: 335–40.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Lyman GH,
    3. Giuliano AE,
    4. Somerfield MR,
    5. Benson III AB,
    6. Bodurka DC,
    7. Burstein HJ, et al.
    American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23: 7703–20.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Krag DN,
    3. Anderson SJ,
    4. Julian TB,
    5. Brown AM,
    6. Harlow SP,
    7. Costantino JP, et al.
    Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010; 11: 927–33.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Krag D.
    Current status of sentinel lymph node surgery for breast cancer. J Natl Cancer. 1999; 91: 302–3.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Kelley LM,
    3. Holmes DR.
    Tracer agents for the detection of sentinel lymph nodes in breast cancer: current concerns and directions for the future. J Surg Oncol. 2011; 104: 91–6.
    OpenUrlPubMed
  12. 12.↵
    2. McCarter MD,
    3. Yeung H,
    4. Yeh S,
    5. Fey J,
    6. Borgen PI,
    7. Cody III HS.
    Localization of the sentinel node in breast cancer: identical results with same-day and day-before isotope injection. Ann Surg Oncol. 2001; 8: 682–6.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Morrow M,
    3. Rademaker AW,
    4. Bethke KP,
    5. Talamonti MS,
    6. Dawes LG,
    7. Clauson J, et al.
    Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery. 1999; 126: 714–22.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. Kitai T,
    3. Inomoto T,
    4. Miwa M,
    5. Shikayama T.
    Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005; 12: 211–5.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Hokimoto N,
    3. Sugimoto T,
    4. Namikawa T,
    5. Funakoshi T,
    6. Oki T,
    7. Ogawa M, et al.
    A novel color fluorescence navigation system for intraoperative transcutaneous lymphatic mapping and resection of sentinel lymph nodes in breast cancer: comparison with the combination of gamma probe scanning and visible dye methods. Oncology. 2018; 94: 99–106.
    OpenUrl
  16. 16.↵
    2. Ahmed M,
    3. Purushotham AD,
    4. Douek M.
    Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014; 15: e351–e362.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Sugie T,
    3. Ikeda T,
    4. Kawaguchi A,
    5. Shimizu A,
    6. Toi M.
    Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol. 2017; 22: 11–7.
    OpenUrl
  18. 18.↵
    2. Yuan L,
    3. Zhou Y,
    4. Hu Y,
    5. Wei HY,
    6. Pan QW,
    7. Zhang KY, et al.
    Clinical application of the combination of indocyanine green and methylene blue in sentinel lymph node mapping. Chin J Breast Dis (Electron Ed). 2016; 10: 87–91.
    OpenUrl
  19. 19.↵
    Chinese Anti-Cancer Association. Guideline and standard for the diagnosis and treatment of breast cancer by Chinese Anti-Cancer Association (2017 edition). China Oncol. 2017; 27: 695–760. Available from: http://kns.cnki.net/kcms/detail/31.1727.R.20170928.1039.004.html.
    OpenUrl
  20. 20.↵
    Chinese Medical Association. Guidelines for sentinel lymph node biopsy using a fluorescence navigation in patients with breast cancer. Chin J Breast Dis (Electronic Edition). 2017; 11: 193–7. Available from: http://zhrhbzz.paperopen.com/oa/DArticle.aspx?type=view&id=20170401.
    OpenUrl
  21. 21.↵
    2. Casarin J,
    3. Multinu F,
    4. Pasupathy K,
    5. Weaver A,
    6. McGree M,
    7. Tortorella L, et al.
    Frozen section for detection of lymph nodes after cervical injection with Indocyanine Green (ICG) for sentinel lymph node technique in endometrial cancer staging. Ann Surg Oncol. 2018; 25: 3692–8.
    OpenUrl
  22. 22.↵
    2. Stradling B,
    3. Aranha G,
    4. Gabram S.
    Adverse skin lesions after methylene blue injections for sentinel lymph node localization. Am J Surg. 2002; 184: 350–2.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Krynyckyi BR,
    3. Miner M,
    4. Ragonese JM,
    5. Firestone M,
    6. Kim CK,
    7. Machac J.
    Technical aspects of performing lymphoscintigraphy: optimization of methods used to obtain images. Clin Nucl Med. 2000; 25: 978–85.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Reinhart MB,
    3. Huntington CR,
    4. Blair LJ,
    5. Heniford BT,
    6. Augenstein VA.
    Indocyanine green: historical context, current applications, and future considerations. Surg Innov. 2016; 23: 166–75.
    OpenUrlCrossRefPubMed
  25. 25.
    2. Sugie T,
    3. Kinoshita T,
    4. Masuda N,
    5. Sawada T,
    6. Yamauchi A,
    7. Kuroi K, et al.
    Evaluation of the clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol. 2016; 23: 44–50.
    OpenUrl
  26. 26.↵
    2. Buda A,
    3. Papadia A,
    4. Zapardiel I,
    5. Vizza E,
    6. Ghezzi F,
    7. De Ponti E, et al.
    From conventional radiotracer Tc-99m with blue dye to indocyanine green fluorescence: a comparison of methods towards optimization of sentinel lymph node mapping in early stage cervical cancer for a laparoscopic approach. Ann Surg Oncol. 2016; 23: 2959–65.
    OpenUrlPubMed
  27. 27.↵
    2. Papadia A,
    3. Zapardiel I,
    4. Bussi B,
    5. Ghezzi F,
    6. Ceccaroni M,
    7. De Ponti E, et al.
    Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye. J Cancer Res Clin Oncol. 2017; 143: 475–80.
    OpenUrlPubMed
  28. 28.
    2. Ruscito I,
    3. Gasparri ML,
    4. Braicu EI,
    5. Bellati F,
    6. Raio L,
    7. Sehouli J, et al.
    Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes-a meta-analysis. Ann Surg Oncol. 2016; 23: 3749–56.
    OpenUrlPubMed
  29. 29.↵
    2. Imboden S,
    3. Papadia A,
    4. Nauwerk M,
    5. McKinnon B,
    6. Kollmann Z,
    7. Mohr S, et al.
    A comparison of radiocolloid and indocyanine green fluorescence imaging, sentinel lymph node mapping in patients with cervical cancer undergoing laparoscopic surgery. Ann Surg Oncol. 2015; 22: 4198–203.
    OpenUrl
  30. 30.↵
    2. Inoue T,
    3. Nishi T,
    4. Nakano Y,
    5. Nishimae A,
    6. Sawai Y,
    7. Yamasaki M, et al.
    Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer. Breast Cancer. 2016; 23: 295–300.
    OpenUrl
  31. 31.↵
    2. Niebling MG,
    3. Pleijhuis RG,
    4. Bastiaannet E,
    5. Brouwers AH,
    6. Van Dam GM,
    7. Hoekstra HJ.
    A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping. Eur J Surg Oncol. 2016; 42: 466–73.
    OpenUrl
  32. 32.↵
    2. Hirche C,
    3. Mohr Z,
    4. Kneif S,
    5. Murawa D,
    6. Hunerbein M.
    High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer. J Surg Oncol. 2012; 105: 162–6.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Straver ME,
    3. Meijnen P,
    4. Van Tienhoven G,
    5. Van De Velde CJH,
    6. Mansel RE,
    7. Bogaerts J, et al.
    Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010; 17: 1854–61.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    2. Goyal A,
    3. Newcombe RG,
    4. Chhabra A,
    5. Mansel RE.
    Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer-results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006; 99: 203–8.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Buda A,
    3. Elisei F,
    4. Palazzi S,
    5. De Ponti E,
    6. Arosio M,
    7. Vecchione F, et al.
    Quality of care for cervical and endometrial cancer patients: the impact of different techniques of sentinel lymph node mapping on patient satisfaction. Ann Surg Oncol. 2016; 23: 2975–81.
    OpenUrl
  36. 36.↵
    Arbeitsgemeinschaft Gynkologische Onkologie. Guidelines of the AGO breast committee: comission mamma.[Accessed April 10, 2017] , Available from: http://www.ago-online.de/en/guidelines-mamma/april-2017/.
  37. 37.↵
    Japan Breast Cancer Society. Breast Cancer Treatment Guidelines.[Accessed April 10, 2017] , Available from: http://jbcs.gr.jp/guidline/guideline/.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords